Clinical Trials Logo

Clinical Trial Summary

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).


Clinical Trial Description

This open-label Phase I study aims at assessing the safety and clinical activity of the NKR-2 treatment administered 3 times with a 2-week interval between each administration in different tumor types. In absence of progressive disease at the first tumor assessment following NKR-2 administratio, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval. The study will contain two consecutive segments: a Phase I dose escalation and a Phase I expansion segment.

The Phase I dose escalation segment will include 2 arms, one in solid tumors and one in hematological tumors. The dose escalation design will include 3 dose levels: The dose escalation phase will consist of 3 cohorts (Cohorts 1-3) for the solid tumors, and 3 cohorts (Cohorts 4-6) for the hematological tumors; with each set of 3 cohorts receiving escalating doses of the NKR-2 therapy.

Two additional cohorts will be added in each dose escalation arm with the aim to provide a more intense treatment during the induction treatment. These additional cohorts in both the solid arm (cohort 8-9 - only in CRC) and in the hematological arm of the study (cohort 10-11 - only in AML/MDS) will therefore evaluate a tighter schedule of NKR-2 injections with the three first injections within the induction cycle separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections. These cohorts will each enroll 3 patients in case of no DLT. Based on safety and early clinical data from these cohorts, the specific schedule of cohorts 8-11 might be selected for the expansion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03018405
Study type Interventional
Source Celyad (formerly named Cardio3 BioSciences)
Contact Amélie Vanneste
Email avanneste@celyad.com
Status Recruiting
Phase Phase 1/Phase 2
Start date December 2016
Completion date August 2021

See also
  Status Clinical Trial Phase
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05442580 - CART-38 in Adult AML and MM Patients Phase 1
Terminated NCT04178902 - A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma Phase 1
Completed NCT02920697 - Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05908409 - A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT04702425 - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Phase 1
Completed NCT00710528 - Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT04721002 - Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Active, not recruiting NCT02240537 - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Phase 1
Active, not recruiting NCT02203643 - Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Phase 2
Completed NCT02211014 - An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Phase 1
Recruiting NCT04649073 - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04123418 - A Study of WVT078 in Patients With Multiple Myeloma (MM) Phase 1
Terminated NCT01663766 - Phase I Study of Milatuzumab for Graft Versus Host Disease Phase 1
Completed NCT01919086 - Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Phase 2
Withdrawn NCT05513612 - Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Phase 1
Completed NCT01413568 - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT00889798 - Tumor Registry of Lymphatic Neoplasia